Pfizer (PFE) Declares $0.41 Dividend
Pfizer said on June 22, 2023 that its board of directors declared a regular quarterly dividend of $0.41 per share ($1.64 annualized). Previously, the company paid $0.41 per share.
Shares must be purchased before the ex-div date of July 27, 2023 to qualify for the dividend. Shareholders of record as of July 28, 2023 will receive the payment on September 5, 2023.
At the current share price of $36.68 / share, the stock's dividend yield is 4.47%.
Looking back five years and taking a sample every week, the average dividend yield has been 3.69%, the lowest has been 2.62%, and the highest has been 5.34%. The standard deviation of yields is 0.48 (n=235).
The current dividend yield is 1.63 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.32. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.08%, demonstrating that it has increased its dividend over time.
Learn to Harvest Dividends
Buy Stock. Capture Dividend. Sell Stock. Repeat. This is the essence of dividend harvesting and you can do it easily with Fintel's Dividend Capture Calendar.
What is the Fund Sentiment?
There are 4488 funds or institutions reporting positions in Pfizer. This is a decrease of 144 owner(s) or 3.11% in the last quarter. Average portfolio weight of all funds dedicated to PFE is 0.65%, a decrease of 3.51%. Total shares owned by institutions decreased in the last three months by 1.30% to 4,424,819K shares. 
The put/call ratio of PFE is 0.99, indicating a bullish outlook.
Analyst Price Forecast Suggests 30.16% Upside
As of June 1, 2023, the average one-year price target for Pfizer is 47.74. The forecasts range from a low of 35.35 to a high of $78.75. The average price target represents an increase of 30.16% from its latest reported closing price of 36.68.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Pfizer is 79,124MM, a decrease of 14.88%. The projected annual non-GAAP EPS is 5.02.
What are Other Shareholders Doing?
Capital World Investors holds 231,512K shares representing 4.10% ownership of the company. In it's prior filing, the firm reported owning 256,097K shares, representing a decrease of 10.62%. The firm decreased its portfolio allocation in PFE by 30.20% over the last quarter.
Wellington Management Group Llp holds 218,932K shares representing 3.88% ownership of the company. In it's prior filing, the firm reported owning 199,330K shares, representing an increase of 8.95%. The firm decreased its portfolio allocation in PFE by 13.57% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 173,954K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 170,636K shares, representing an increase of 1.91%. The firm decreased its portfolio allocation in PFE by 25.05% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 130,981K shares representing 2.32% ownership of the company. In it's prior filing, the firm reported owning 129,764K shares, representing an increase of 0.93%. The firm decreased its portfolio allocation in PFE by 25.46% over the last quarter.
Geode Capital Management holds 109,853K shares representing 1.95% ownership of the company. In it's prior filing, the firm reported owning 109,276K shares, representing an increase of 0.53%. The firm decreased its portfolio allocation in PFE by 25.97% over the last quarter.
Pfizer Background Information
(This description is provided by the company.)
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.
Key filings for this company:
This story originally appeared on Fintel.